Bli medlem
Bli medlem

Du är här

2016-10-17

Oxford Immunotec Schedules Third Quarter 2016 Earnings Release and Conference Call for November 1, 2016

Oxford Immunotec
Press release

Oxford Immunotec Schedules Third Quarter 2016 Earnings Release and Conference
Call for November 1, 2016

OXFORD, United Kingdom and MARLBOROUGH, Mass., 2016-10-17 17:25 CEST (GLOBE
NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth
diagnostics company focused on developing and commercializing proprietary tests
for the management of under-served immune-regulated conditions, today announced
that it plans to release third quarter 2016 financial results prior to market
open on Tuesday, November 1, 2016. Dr. Peter Wrighton-Smith, Chief Executive
Officer, and Rick Altieri, Chief Financial Officer, will host a conference call
to review the Company's results at 8:00 a.m. Eastern Time the same day. The
call will be concurrently webcast.

To listen to the conference call on your telephone, please dial (855) 363-5047
for United States callers and +1 (484) 365-2897 for international callers and
reference confirmation code 91830521, approximately ten minutes prior to start
time. To access the live audio webcast or subsequent archived recording, visit
the Investor Relations section of Oxford Immunotec's website at
www.oxfordimmunotec.com. The replay will be available on the Company's website
for approximately 60 days.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company
focused on developing and commercializing proprietary tests for the management
of under-served immune-regulated conditions. The Company's first product is the
TSPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB
test has been approved for sale in over 50 countries, including the United
States, where it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well as Japan and
China. The company's second product line is a range of assays for tick-borne
diseases, such as Lyme disease, obtained through the acquisition of Imugen. The
T-SPOT.CMV test and the T-SPOT.PRT test are part of the Company's third product
line focused on the transplantation market. In addition to these three product
lines, the Company has additional active development programs in other
immune-regulated conditions. The Company is headquartered near Oxford, U.K. and
in Marlborough, Mass. Additional information can be found at
www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

CONTACTS:

For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
ccrawley@oxfordimmunotec.com

For Investor Inquiries:
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
raltieri@oxfordimmunotec.com

Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0501
oxfordimmunotec@westwicke.com

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.